Phase 2
N=25
Respiratory Kinematics During Voluntary and Reflex Cough in Healthy Adults
Cough
Bottom Line
View on ClinicalTrials.gov: NCT01854268 ↗Enrolled (actual)
25
Serious AEs
0.0%
Results posted
Mar 2015
Primary outcome: Primary: Lung Volume Initiation — 23.3 % Vital Capacity, relative to EEL
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Healthy adults who receive capsaicin (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Florida
- Primary completion
- May 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Lung Volume Initiation |
23.3 | — |
| SECONDARY Peak Expiratory Airflow Rate |
6.058; 5.437 | — |
| SECONDARY Urge-to-cough |
6 | — |
Summary
Cough is a defensive behavior that involves three stages. A large inspiratory phase, a compression phase where the vocal folds close and subglottal pressure is developed, and an expiratory phase. Cough serves to protect the upper and lower airways from material such as liquids, solids, or saliva, that have been aspirated. There are two types of cough: voluntary and reflex cough. Voluntary cough involves a cough to command. Reflex cough is a cough that is generated secondary to a stimulus in or near the airway. There has been some research regarding the differences between voluntary and reflex cough. However, no research has described the differences in airflow or movement pattern (kinematics) between the two types of cough. This study seeks to determine the respiratory kinematics and airflow differences between voluntary and reflex cough in healthy participants.
Eligibility Criteria
Inclusion Criteria
- Healthy adults between the ages of 18-80 years.
- Ability to provide informed consent.
Exclusion Criteria
- No history of smoking within the last 5 years as this reduces the sensitivity to capsaicin
- No history of neurological disease (i.e. Parkinson's disease, stroke, traumatic brain injury, etc.)
- No known allergy to capsaicin
- No history of respiratory disease (i.e. asthma, chronic obstructive pulmonary disease, or respiratory infection within the last 5 weeks.)
Data sourced from ClinicalTrials.gov (NCT01854268). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.